BAD and ovarian carcinoma: Furthermore, we have previously demonstrated that ovarian cancer samples from patients categorized as incomplete responders to primary platinum therapy have a decreased expression of the BAD protein Ser-155 phosphatase, PP2C, compared to samples from patients categorized as complete responders (14).